, Tracking Stock Market Picks
Enter Symbol:
Avanir Pharmaceuticals (AVNR) [hlAlert]

up 521.24 %

Avanir Pharmaceuticals (AVNR) rated Buy with price target $10 by Jefferies

Posted on: Thursday,  Jul 1, 2010  8:25 AM ET by Jefferies

Jefferies rated Buy Avanir Pharmaceuticals (NASDAQ: AVNR) on 07/01/2010, when the stock price was $2.73. Since
then, Avanir Pharmaceuticals has gained 521.25% as of 01/12/2015's recent price of $16.96.
If you would have followed this Jefferies's recommendation on AVNR, you would have gained 521.24% of your investment in 1656 days.

Avanir Pharmaceuticals is a pharmaceutical company focused on developing, acquiring and commercializing therapeutic products for the treatment of chronic diseases. The Company?s product candidates address therapeutic markets that include the central nervous system and inflammatory diseases. Its principal product candidate, Zenviatm (dextromethorphan hydrobromide/quinidine sulfate), is in Phase III clinical development for the treatment of pseudobulbar affect (PBA) and diabetic peripheral neuropathic pain (DPN pain). The Company?s first commercialized product, docosanol 10% cream, (sold as Abreva by its marketing partner GlaxoSmithKline Consumer Healthcare in North America) is an over-the-counter treatment for cold sores that has been approved by the United States Food and Drug Administration (FDA).

Jefferiess' research efforts cover U.S. & International equity, high yield, convertibles, derivatives and option strategies, investment grade fixed income, post-reorganization securities, as well as special situations and quantitative research. Our team of more than 150 research professionals covers nearly 1,200 companies in more than 40 industries worldwide. Our analysts focus on identifying emerging industry themes while providing in-depth, thought provoking, objective research.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
7/1/2010 8:25 AM Buy
2.73 10.00
as of 12/31/2010
1 Week down  -2.58 %
1 Month down  -2.58 %
3 Months up  29.78 %
1 YTD up  51.64 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy